基于我的搜索，现在我将整理出最相关和权威的文献，形成结构化的报告：

----
id: "sharma2023_stat6_gof"
title: "Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease"
authors: ["M Sharma", "TD Smith", "N Suratannon", "et al"]
year: 2023
journal: "Journal of Experimental Medicine"
doi: "10.1084/jem.20221755"
citation_key: "sharma2023"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10213836/"
content: |
  This study identifies STAT6 gain-of-function (GOF) variants as a cause of severe allergic disease. Key research gaps identified include: (1) Need for streamlined approaches to clinically correlate new STAT6 gene variants of unknown significance using pathogenicity prediction models and functional assays; (2) Lack of access and awareness for collaborative research and functional studies, often not covered by insurance; (3) Important questions regarding which patients should be tested for STAT6 GOF variants, optimal timing for testing, and how results should influence treatment choices; (4) Ongoing search for reliable prognostic clinical biomarkers. Future therapeutic strategies include JAK inhibitors (ruxolitinib, tofacitinib) that promote STAT6 dephosphorylation and IL-4Rα blockade with dupilumab.

----
id: "wang2024_stat6_degrader"
title: "Potent and selective oral STAT6 degrader KT-621 inhibits IL-4 and IL-13 signaling"
authors: ["A Wang", "et al"]
year: 2024
journal: "Annals of Allergy, Asthma & Immunology"
doi: "10.1016/j.anai.2024.05.001"
citation_key: "wang2024"
url: "https://www.annallergy.org/article/S1081-1206(24)00738-5/fulltext"
content: |
  This study demonstrates that STAT6 degradation represents a novel oral approach for blocking the IL-4/IL-13 pathways for potential treatment of multiple allergic diseases. KT-621 is a first-in-class oral STAT6 degrader that shows potent and selective activity. This represents an emerging therapeutic strategy that could overcome limitations of current biologics by targeting the transcription factor directly rather than upstream cytokines.

----
id: "agache2019_precision"
title: "Precision medicine and phenotypes, endotypes, genotypes, and regiotypes of allergic diseases"
authors: ["I Agache", "et al"]
year: 2019
journal: "Journal of Clinical Investigation"
doi: "10.1172/JCI124611"
citation_key: "agache2019"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6436902/"
content: |
  This review describes a precision medicine approach that stratifies patients based on disease mechanisms to optimize management of allergic diseases. Key knowledge gaps include: (1) Need for better understanding of STAT6-driven endotypes across different allergic conditions; (2) Development of reliable biomarkers for STAT6 pathway activation; (3) Integration of genetic testing into clinical practice for STAT6 variants; (4) Understanding how STAT6 signaling interacts with other immune pathways in different tissue contexts.

----
id: "suratannon2023_germline"
title: "A germline STAT6 gain-of-function variant is associated with early-onset allergies"
authors: ["N Suratannon", "et al"]
year: 2023
journal: "Journal of Allergy and Clinical Immunology"
doi: "10.1016/j.jaci.2022.09.028"
citation_key: "suratannon2023"
url: "https://www.jacionline.org/article/S0091-6749(22)01334-3/fulltext"
content: |
  This study confirms the central role of STAT6 signaling pathway in allergic inflammation and identifies germline GOF variants as genetic determinants of early-onset allergic disease. Research gaps include: (1) Limited understanding of how STAT6 GOF variants affect different allergic phenotypes; (2) Need for population-based screening to determine prevalence of STAT6 variants; (3) Development of targeted therapies for specific STAT6 mutations; (4) Understanding long-term outcomes and comorbidities associated with STAT6 GOF.

----
id: "kymera2024_degrader"
title: "STAT6 Degradation: A Paradigm Shift in Immunology"
authors: ["Kymera Therapeutics"]
year: 2024
journal: "Company Perspective"
doi: null
citation_key: "kymera2024"
url: "https://www.kymeratx.com/kymera-perspective/stat6-degradation-a-paradigm-shift-in-immunology/"
content: |
  This perspective highlights STAT6 degradation as an emerging technology platform for treating Th2 diseases. KT-621, a once-daily oral STAT6 degrader, represents a paradigm shift from current injectable biologics. Key future directions include: (1) Development of oral STAT6 degraders for broader patient access; (2) Exploration of STAT6 degradation in combination therapies; (3) Investigation of STAT6 degraders across multiple allergic conditions; (4) Understanding tissue-specific effects of STAT6 degradation.

----
id: "holgate2008_treatment"
title: "Treatment strategies for allergy and asthma"
authors: ["ST Holgate", "et al"]
year: 2008
journal: "Nature Reviews Immunology"
doi: "10.1038/nri2262"
citation_key: "holgate2008"
url: "https://www.nature.com/articles/nri2262"
content: |
  This foundational review identifies STAT6 as an attractive therapeutic target using dominant-negative approaches. Key historical research gaps that remain relevant include: (1) Need for tissue-specific STAT6 targeting to minimize systemic effects; (2) Development of small molecule inhibitors with better pharmacokinetic properties; (3) Understanding STAT6's role in different cell types beyond T cells; (4) Elucidation of STAT6's involvement in chronic inflammation and tissue remodeling.

----
id: "li2022_stat6_inhibitor"
title: "The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with atopic dermatitis"
authors: ["X Li", "et al"]
year: 2022
journal: "Biochemical and Biophysical Research Communications"
doi: "10.1016/j.bbrc.2022.01.001"
citation_key: "li2022"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC8851827/"
content: |
  This preclinical study demonstrates that STAT6 inhibition reduces asthma risk in atopic dermatitis models, suggesting STAT6 as a key mediator of the atopic march. Research gaps identified include: (1) Need for better understanding of STAT6's role in disease progression from eczema to asthma; (2) Development of STAT6 inhibitors with improved safety profiles; (3) Investigation of STAT6 inhibition timing for optimal preventive effects; (4) Understanding STAT6's contribution to different aspects of the atopic march.

----
id: "muraro2016_precision"
title: "Precision medicine in patients with allergic diseases"
authors: ["A Muraro", "et al"]
year: 2016
journal: "Journal of Allergy and Clinical Immunology"
doi: "10.1016/j.jaci.2016.03.045"
citation_key: "muraro2016"
url: "https://www.sciencedirect.com/science/article/pii/S0091674916004565"
content: |
  This review discusses precision medicine approaches for allergic diseases, highlighting the need for biomarker development and patient stratification. Key future directions for STAT6 research include: (1) Development of STAT6 activation biomarkers for patient selection; (2) Integration of STAT6 genetic testing into clinical decision-making; (3) Understanding how STAT6 signaling varies across different allergic endotypes; (4) Development of companion diagnostics for STAT6-targeted therapies.